Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer's disease.

Sun N, Mormino EC, Chen J, Sabuncu MR, Yeo BTT; Alzheimer’s Disease Neuroimaging Initiative.

Neuroimage. 2019 Jul 22;201:116043. doi: 10.1016/j.neuroimage.2019.116043. [Epub ahead of print]

PMID:
31344486
2.

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study.

Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, Cosio DMO, Farrell M, Quiroz YT, Mormino EC, Buckley RF, Papp KV, Amariglio RA, Dewachter I, Ivanoiu A, Huijbers W, Hedden T, Marshall GA, Chhatwal JP, Rentz DM, Sperling RA, Johnson K.

JAMA Neurol. 2019 Jun 3. doi: 10.1001/jamaneurol.2019.1424. [Epub ahead of print]

3.

Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid.

Buckley RF, Mormino EC, Chhatwal J, Schultz AP, Rabin JS, Rentz DM, Acar D, Properzi MJ, Dumurgier J, Jacobs H, Gomez-Isla T, Johnson KA, Sperling RA, Hanseeuw BJ; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Jun;78:178-185. doi: 10.1016/j.neurobiolaging.2019.02.019. Epub 2019 Mar 7.

PMID:
30947113
4.

An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults.

Yang HS, Chhatwal JP, Xu J, White CC, Hanseeuw B, Rabin JS, Papp KV, Buckley RF, Schultz AP, Properzi MJ, Gatchel JR, Amariglio RE, Donovan NJ, Mormino EC, Hedden T, Marshall GA, Rentz DM, Johnson KA, De Jager PL, Sperling RA.

J Alzheimers Dis. 2019;68(3):1161-1170. doi: 10.3233/JAD-180788.

5.

Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.

Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA.

JAMA Neurol. 2019 May 1;76(5):542-551. doi: 10.1001/jamaneurol.2018.4693.

PMID:
30715078
6.

Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.

Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP, Yokoyama JS, Rabinovici GD, Miller BL, Yaffe K, Schellenberg GD, Kauppi K, Holland D, McEvoy LK, Kukull WA, Tosun D, Weiner MW, Sperling RA, Bennett DA, Hyman BT, Andreassen OA, Dale AM, Desikan RS; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2019 Feb 1;142(2):460-470. doi: 10.1093/brain/awy327.

PMID:
30689776
7.

The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, Hanseeuw BJ, Buckley R, Chhatwal J, Hedden T, Marshall GA, Quiroz YT, Donovan NJ, Jackson J, Gatchel JR, Rabin JS, Jacobs H, Yang HS, Properzi M, Kirn DR, Rentz DM, Johnson KA.

Ann Neurol. 2019 Feb;85(2):181-193. doi: 10.1002/ana.25395. Epub 2019 Jan 21.

PMID:
30549303
8.

Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers.

Properzi MJ, Buckley RF, Chhatwal JP, Donohue MC, Lois C, Mormino EC, Johnson KA, Sperling RA, Schultz AP.

Neuroimage. 2019 Feb 1;186:446-454. doi: 10.1016/j.neuroimage.2018.11.019. Epub 2018 Nov 17.

PMID:
30458305
9.

Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.

Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A, Wen N, Hess CP, Dillon WP, Glastonbury CM, Glymour M, Yokoyama JS, Elahi FM, Rabinovici GD, Miller BL, Mormino EC, Sperling RA, Bennett DA, McEvoy LK, Brewer JB, Feldman HH, Hyman BT, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Schellenberg GD, Yaffe K, Sugrue LP, Dale AM, Posthuma D, Andreassen OA, Karch CM, Desikan RS.

Acta Neuropathol. 2019 Feb;137(2):209-226. doi: 10.1007/s00401-018-1928-6. Epub 2018 Nov 9.

10.

Amyloid-associated increases in longitudinal report of subjective cognitive complaints.

Amariglio RE, Buckley RF, Mormino EC, Marshall GA, Johnson KA, Rentz DM, Sperling RA.

Alzheimers Dement (N Y). 2018 Sep 6;4:444-449. doi: 10.1016/j.trci.2018.08.005. eCollection 2018.

11.

A New Tool for Clinical Neuroscience-Synaptic Imaging.

Mormino EC, Jagust WJ.

JAMA Neurol. 2018 Oct 1;75(10):1181-1183. doi: 10.1001/jamaneurol.2018.1643. No abstract available.

PMID:
30014142
12.

Understanding the impact of sex and gender in Alzheimer's disease: A call to action.

Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, Mallampalli MP, Mormino EC, Scott L, Yu WH, Maki PM, Mielke MM.

Alzheimers Dement. 2018 Sep;14(9):1171-1183. doi: 10.1016/j.jalz.2018.04.008. Epub 2018 Jun 12.

13.

Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.

Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, Doré V, Dobson A, Masters CL, Waller M, Rowe CC, Maruff P, Donohue MC, Rentz DM, Kirn D, Hedden T, Chhatwal J, Schultz AP, Johnson KA, Villemagne VL, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging, Biomarker and Lifestyle study of ageing; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.

PMID:
29803541
14.

PET staging of amyloidosis using striatum.

Hanseeuw BJ, Betensky RA, Mormino EC, Schultz AP, Sepulcre J, Becker JA, Jacobs HIL, Buckley RF, LaPoint MR, Vannini P, Donovan NJ, Chhatwal JP, Marshall GA, Papp KV, Amariglio RE, Rentz DM, Sperling RA, Johnson KA; Alzheimer's Disease Neuroimaging Initiative; Harvard Aging Brain Study.

Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21.

15.
16.

The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults.

Orlovsky I, Huijbers W, Hanseeuw BJ, Mormino EC, Hedden T, Buckley RF, LaPoint M, Rabin JS, Rentz DM, Johnson KA, Sperling RA, Papp KV.

Alzheimers Dement (Amst). 2017 Nov 23;10:121-129. doi: 10.1016/j.dadm.2017.11.003. eCollection 2018.

17.

Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?

Hansson O, Mormino EC.

Brain. 2018 May 1;141(5):1241-1244. doi: 10.1093/brain/awy065. No abstract available.

18.

Dissociable influences of APOE ε4 and polygenic risk of AD dementia on amyloid and cognition.

Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino EC; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 May 1;90(18):e1605-e1612. doi: 10.1212/WNL.0000000000005415. Epub 2018 Mar 28.

19.

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.

Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC.

Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677. doi: 10.1016/j.trci.2017.10.004. eCollection 2017 Nov.

20.

Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.

Tan CH, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP, Dillon WP, Bonham LW, Yokoyama JS, Karch CM, Brewer JB, Rabinovici GD, Miller BL, Schellenberg GD, Kauppi K, Feldman HA, Holland D, McEvoy LK, Hyman BT, Bennett DA, Andreassen OA, Dale AM, Desikan RS; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2018 Jan;135(1):85-93. doi: 10.1007/s00401-017-1789-4. Epub 2017 Nov 24.

21.

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.

Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.

JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216.

22.

APOE genotype and early β-amyloid accumulation in older adults without dementia.

Lim YY, Mormino EC; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 Sep 5;89(10):1028-1034. doi: 10.1212/WNL.0000000000004336. Epub 2017 Aug 9.

23.

Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals.

Schultz AP, Chhatwal JP, Hedden T, Mormino EC, Hanseeuw BJ, Sepulcre J, Huijbers W, LaPoint M, Buckley RF, Johnson KA, Sperling RA.

J Neurosci. 2017 Apr 19;37(16):4323-4331. doi: 10.1523/JNEUROSCI.3263-16.2017. Epub 2017 Mar 17.

24.

Cued memory decline in biomarker-defined preclinical Alzheimer disease.

Papp KV, Rentz DM, Mormino EC, Schultz AP, Amariglio RE, Quiroz Y, Johnson KA, Sperling RA.

Neurology. 2017 Apr 11;88(15):1431-1438. doi: 10.1212/WNL.0000000000003812. Epub 2017 Mar 10.

25.

Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline.

Hanseeuw BJ, Betensky RA, Schultz AP, Papp KV, Mormino EC, Sepulcre J, Bark JS, Cosio DM, LaPoint M, Chhatwal JP, Rentz DM, Sperling RA, Johnson KA.

Ann Neurol. 2017 Apr;81(4):583-596. doi: 10.1002/ana.24910. Epub 2017 Apr 6.

26.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, Sperling RA.

Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.

27.

Introduction to special edition, "State of the Field: Advances in Neuroimaging from the 2016 Alzheimer's Imaging Consortium".

Mormino EC, Wolk DA, Apostolova LG.

Alzheimers Dement (Amst). 2016 Dec 21;5:67-69. doi: 10.1016/j.dadm.2016.12.008. eCollection 2016. No abstract available.

28.

Asymptomatic Alzheimer disease: Defining resilience.

Hohman TJ, McLaren DG, Mormino EC, Gifford KA, Libon DJ, Jefferson AL; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Dec 6;87(23):2443-2450. Epub 2016 Nov 4.

29.

Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.

Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BT; Alzheimer’s Disease Neuroimaging Initiative.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6535-E6544. Epub 2016 Oct 4.

30.

Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance.

Rentz DM, Mormino EC, Papp KV, Betensky RA, Sperling RA, Johnson KA.

Brain Imaging Behav. 2017 Apr;11(2):383-390. doi: 10.1007/s11682-016-9640-4.

31.

Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.

Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, Sperling RA.

JAMA Neurol. 2016 Oct 1;73(10):1185-1191. doi: 10.1001/jamaneurol.2016.2237.

32.

Polygenic risk of Alzheimer disease is associated with early- and late-life processes.

Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Aug 2;87(5):481-8. doi: 10.1212/WNL.0000000000002922. Epub 2016 Jul 6.

33.

Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly.

Hsu DC, Mormino EC, Schultz AP, Amariglio RE, Donovan NJ, Rentz DM, Johnson KA, Sperling RA, Marshall GA; Harvard Aging Brain Study.

J Alzheimers Dis. 2016 Jun 18;53(3):1097-105. doi: 10.3233/JAD-150987.

34.

Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials.

Mormino EC, Papp KV.

JAMA Neurol. 2016 Jun 1;73(6):640-2. doi: 10.1001/jamaneurol.2016.0281. No abstract available.

PMID:
27064971
35.

Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, Frisoni GB, Jagust W, Mormino EC, Petersen RC, Sperling RA, van der Flier WM, Villemagne VL, Visser PJ, Vos SJ.

Nat Rev Neurol. 2016 Feb;12(2):117-24. doi: 10.1038/nrneurol.2015.251. Epub 2016 Jan 18. Review.

36.

Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease.

Papp KV, Mormino EC, Amariglio RE, Munro C, Dagley A, Schultz AP, Johnson KA, Sperling RA, Rentz DM.

Neuropsychology. 2016 Jul;30(5):624-30. doi: 10.1037/neu0000246. Epub 2015 Nov 23.

37.

Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly.

Amariglio RE, Mormino EC, Pietras AC, Marshall GA, Vannini P, Johnson KA, Sperling RA, Rentz DM.

Neurology. 2015 Jul 7;85(1):56-62. doi: 10.1212/WNL.0000000000001712. Epub 2015 Jun 5.

38.

Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.

Papp KV, Amariglio RE, Mormino EC, Hedden T, Dekhytar M, Johnson KA, Sperling RA, Rentz DM.

Neuropsychologia. 2015 Jul;73:169-75. doi: 10.1016/j.neuropsychologia.2015.04.034. Epub 2015 May 19.

39.

Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.

Donovan NJ, Hsu DC, Dagley AS, Schultz AP, Amariglio RE, Mormino EC, Okereke OI, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Alzheimers Dis. 2015;46(1):63-73. doi: 10.3233/JAD-142940.

40.

Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.

Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, Amariglio RE, Marshall GA, Rentz DM, Johnson KA, Sperling RA.

Brain. 2015 Apr;138(Pt 4):1023-35. doi: 10.1093/brain/awv007. Epub 2015 Feb 11.

41.

A kernel machine method for detecting effects of interaction between multidimensional variable sets: an imaging genetics application.

Ge T, Nichols TE, Ghosh D, Mormino EC, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Apr 1;109:505-514. doi: 10.1016/j.neuroimage.2015.01.029. Epub 2015 Jan 16.

42.

Multiple Brain Markers are Linked to Age-Related Variation in Cognition.

Hedden T, Schultz AP, Rieckmann A, Mormino EC, Johnson KA, Sperling RA, Buckner RL.

Cereb Cortex. 2016 Apr;26(4):1388-400. doi: 10.1093/cercor/bhu238. Epub 2014 Oct 14.

43.

Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA.

JAMA Neurol. 2014 Nov;71(11):1379-85. doi: 10.1001/jamaneurol.2014.2031.

44.

Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits.

Ward AM, Mormino EC, Huijbers W, Schultz AP, Hedden T, Sperling RA.

Neurobiol Aging. 2015 Jan;36(1):265-72. doi: 10.1016/j.neurobiolaging.2014.06.028. Epub 2014 Jul 3.

45.

The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations.

Mormino EC.

Neuropsychol Rev. 2014 Sep;24(3):300-12. doi: 10.1007/s11065-014-9267-4. Epub 2014 Aug 10. Review.

46.

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.

Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, Rentz DM, Johnson KA, Sperling RA; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing; Harvard Aging Brain Study.

Neurology. 2014 May 20;82(20):1760-7. doi: 10.1212/WNL.0000000000000431. Epub 2014 Apr 18.

47.

Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults.

Huijbers W, Mormino EC, Wigman SE, Ward AM, Vannini P, McLaren DG, Becker JA, Schultz AP, Hedden T, Johnson KA, Sperling RA.

J Neurosci. 2014 Apr 9;34(15):5200-10. doi: 10.1523/JNEUROSCI.3579-13.2014.

48.

Cognitively stimulating activities to keep dementia at bay.

Vemuri P, Mormino EC.

Neurology. 2013 Jul 23;81(4):308-9. doi: 10.1212/WNL.0b013e31829c5f05. Epub 2013 Jul 3. No abstract available.

PMID:
23825176
49.

The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ.

Alzheimers Dement. 2013 Nov;9(6):687-698.e1. doi: 10.1016/j.jalz.2012.10.012. Epub 2013 Mar 7.

50.

Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.

Hedden T, Mormino EC, Amariglio RE, Younger AP, Schultz AP, Becker JA, Buckner RL, Johnson KA, Sperling RA, Rentz DM.

J Neurosci. 2012 Nov 14;32(46):16233-42. doi: 10.1523/JNEUROSCI.2462-12.2012.

Supplemental Content

Loading ...
Support Center